MKI67 and cancer: We observed a decreasing frequency of live cancer cells (CD45−) within the tumor and found a significant (P < 0.0001) decrease in proliferating (Ki67+) cancer cells, consistent with the potent antitumor effects induced by AP-diABZI as well as gene expression analysis supporting increased cancer cell death.